These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 25491470)

  • 21. Dose-dependent impulse control disorders in piribedil overdose.
    Giugni JC; Tschopp L; Escalante V; Micheli F
    Clin Neuropharmacol; 2012; 35(1):49-50. PubMed ID: 22240861
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of dopamine agonist dose and gender on the prognosis of impulse control disorders in Parkinson's disease.
    Joutsa J; Martikainen K; Vahlberg T; Kaasinen V
    Parkinsonism Relat Disord; 2012 Dec; 18(10):1079-83. PubMed ID: 22784693
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Dopamine dysregulation syndrome in Parkinson's disease and restless legs syndrome].
    Bayard S; Cochen De Cock V; Dauvillers Y
    Geriatr Psychol Neuropsychiatr Vieil; 2011 Jun; 9(2):227-35. PubMed ID: 21690031
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Hallucinations in Parkinson's disease].
    Moser A; Hagenah J; Kömpf D
    Nervenarzt; 2003 Apr; 74(4):376-85, quiz 385-6. PubMed ID: 12707709
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New treatments for the motor symptoms of Parkinson's disease.
    Vijverman AC; Fox SH
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):761-77. PubMed ID: 25318835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Duration of L-dopa and dopamine agonist monotherapy in Parkinson's disease.
    Nissen T; Newman EJ; Grosset KA; Daghem M; Pal G; Stewart M; Odin P; Macphee GJ; Grosset DG
    Scott Med J; 2012 Nov; 57(4):217-20. PubMed ID: 23002158
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Should levodopa be used anymore?
    Zegers de Beyl D
    Acta Neurol Belg; 2002 Dec; 102(4):163-6. PubMed ID: 12534242
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Valproate for the treatment of medication-induced impulse-control disorders in three patients with Parkinson's disease.
    Hicks CW; Pandya MM; Itin I; Fernandez HH
    Parkinsonism Relat Disord; 2011 Jun; 17(5):379-81. PubMed ID: 21459656
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug-induced impulse control disorders in Parkinson's disease.
    Reiff J; Jost WH
    J Neurol; 2011 May; 258(Suppl 2):S323-7. PubMed ID: 21560063
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Current treatment strategies for Parkinson's disease].
    Südmeyer M; Wojtecki L; Schnitzler A
    Fortschr Neurol Psychiatr; 2011 Dec; 79(12):733-43. PubMed ID: 22161168
    [No Abstract]   [Full Text] [Related]  

  • 31. Levodopa infusion improves impulsivity and dopamine dysregulation syndrome in Parkinson's disease.
    Catalán MJ; de Pablo-Fernández E; Villanueva C; Fernández-Diez S; Lapeña-Montero T; García-Ramos R; López-Valdés E
    Mov Disord; 2013 Dec; 28(14):2007-10. PubMed ID: 24123193
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pathological behaviors provoked by dopamine agonist therapy of Parkinson's disease.
    Ahlskog JE
    Physiol Behav; 2011 Jul; 104(1):168-72. PubMed ID: 21557955
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Medication-related impulse control and repetitive behaviors in Parkinson's disease.
    Voon V; Potenza MN; Thomsen T
    Curr Opin Neurol; 2007 Aug; 20(4):484-92. PubMed ID: 17620886
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Three cases of impulse control disorder in Parkinson's disease patients receiving dopamine replacement therapy.
    Wilson L; Sheehan J; Thorpe M
    Ir Med J; 2013 Jan; 106(1):24-5. PubMed ID: 23472375
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuropsychiatric effects of Parkinson's disease treatment.
    Aarons S; Peisah C; Wijeratne C
    Australas J Ageing; 2012 Sep; 31(3):198-202. PubMed ID: 22950594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Should impulse control disorders and dopamine dysregulation syndrome be indications for deep brain stimulation and intestinal levodopa?
    Okun MS; Weintraub D
    Mov Disord; 2013 Dec; 28(14):1915-9. PubMed ID: 24243803
    [No Abstract]   [Full Text] [Related]  

  • 37. Drugs for Parkinson's disease.
    Treat Guidel Med Lett; 2013 Nov; 11(135):101-6. PubMed ID: 24165688
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study.
    Weintraub D; Sohr M; Potenza MN; Siderowf AD; Stacy M; Voon V; Whetteckey J; Wunderlich GR; Lang AE
    Ann Neurol; 2010 Dec; 68(6):963-8. PubMed ID: 21154480
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Management of Parkinson's disease in 2009].
    Maertens de Noordhout A
    Rev Med Suisse; 2009 Aug; 5(214):1650-5. PubMed ID: 19772196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Levodopa in the treatment of Parkinson's disease: current status and new developments.
    Salat D; Tolosa E
    J Parkinsons Dis; 2013 Jan; 3(3):255-69. PubMed ID: 23948989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.